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Abstract
Hepatitis E virus (HEV) is highly endemic in several African countries with high mortality rate
among pregnant women. Nothing is known about the circulation of this virus in central Africa. We
evaluated therefore the prevalence of anti-HEV IgG in samples collected from pregnant women
living in the five main cities of Gabon, central Africa. We found that 14.1% (119/840) of pregnant
women had anti-HEV IgG. The prevalence differed between regions and between age groups. In
391 newly collected samples from the region where the highest prevalence was found, a significant
difference (p < 0.05) in seroprevalence was found between rural (6.4%) and urban (13.5%) areas.
These data provide evidence of a high prevalence of HEV in Gabon, providing indirect evidence of
past contact with this virus.
Findings
Hepatitis E virus (HEV) is an enterically transmitted path-
ogen and is responsible for recent large-scale epidemics of
hepatitis around the world, as reported recently in
Uganda http://www.promedmail.org, where more than
7500 cases were registered in 1 year [1]. HEV induces self-
limiting or acute hepatitis, and the severity can varied
from no symptoms to fulminating infection [2]. HEV
infections have not been known to become chronic [2];
however, recently, persistent HEV infection, with chronic
hepatitis and cirrhosis, has been reported in patients with
reduced immune surveillance induced by chemotherapy
or post-transplant immune suppression [3,4]. The average
mortality rate from HEV infection is 1–4%, principally
among adolescents and young adults, but it is still not
clear that the severity is age-dependent. For unknown rea-
sons, the mortality rate is higher among pregnant women,
especially during the third trimester [5]. In Sudan, a
case:fatality ratio of 17.8% was found in an outbreak in
Darfur, with a ratio of 31.1% among pregnant women [6].
In endemic areas, which include Africa, Asia and the Mid-
dle East, HEV outbreaks are waterborne, whereas in non-
endemic areas such as Europe, Japan and the USA, spo-
radic cases of acute hepatitis are usually due to zoonotic
foodborne transmission [7]. Bloodborne and perinatal
transmission could also occur, but ingestion of fecally-
contaminated water remains the main route of HEV trans-
mission. Many HEV outbreaks have been observed in
Africa, such as in Ethiopia and Somalia in 1988–1989,
Djibouti in 1993, Morocco in 1994, Chad and Sudan in
2004–2005, the Democratic Republic of the Congo in
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2006 and Uganda in 2007–2008 [1,8-12]. In the absence
of outbreaks, the HEV prevalence in rural populations was
4.4% in Ghana, 14.0% in Burundi, 15.3% in South Africa
and 67.7% in Egypt, with a seroprevalence of up to 84.3%
among pregnant women [13-16]. There appear to be con-
siderable differences in exposure to HEV in endemic areas.
Few data are available on the circulation of HEV in central
Africa. In 1995, no anti-HEV IgG was found in samples
collected in Libreville, the capital of Gabon [17], but the
study was based on a small sample and did not reflect the
actual situation in the country. Furthermore, the labora-
tory techniques for HEV detection have advanced consid-
erably since the time of that study. The aim of the study
reported here was to evaluate the prevalence of anti-HEV
IgG in samples collected from pregnant women living in
the five main cities of Gabon. We also compared the HEV
prevalence in rural and urban areas in the region with the
highest seroprevalence.
Gabon is located on the Gulf of Guinea near the Equator,
and tropical forest covers three quarters of the territory. To
evaluate the HEV prevalence among pregnant women,
two epidemiological surveys were conducted. The first
was conducted from January to March 2005, when blood
samples were collected from all 840 pregnant women
(mean age, 24.6 ± 6.4 years; range, 14–44 years) who
attended a first antenatal examination in the five main cit-
ies of the country: Libreville, the capital city in the north-
west; Port-Gentil, the main harbor and economic capital
in the west; Lambaréné, in the centre of the country;
Oyem in the north-east and Franceville in the south-east.
The second study was conducted from January to June
2007 in rural and urban areas of Franceville, where the
highest seroprevalence was found. The study obtained
ethical clearance from the ethics committee; data on age
and geographic origin were retained only after informed
consent had been obtained.
To determine the anti-HEV IgG prevalence, we used the
HEV (TMB) ELISA Kit (Genelabs Diagnostics, Singapore)
according to the manufacturer's instructions. Serological
status in relation to the age group and geographical origin
of the pregnant women was analysed statistically by the
chi-squared test with Yates correction, and prevalences
and odds ratios were calculated. The corresponding 95%
confidence intervals (CIs) were reported as measures of
statistical significance. Analyses were performed with Epi-
Info (version 6.04dfr, ENSP-Epiconcept-InUS, 2001).
Anti-HEV IgG were found in 119 of the 840 samples
(14.1%). The seroprevalence varied substantially, from
10.2% to 20.8%, by region (Table 1). The highest preva-
lence was found in Franceville, where the risk for contract-
ing HEV infection was twice as high as in the other cities
(Table 1). The seroprevalence was highest in the younger
(14–20 years; 14.8%) and older (31–44 years; 16.8%) age
groups than in the others (Table 1). However, there was
no statistically significant difference in prevalence by age
group.
Despite the high HEV prevalence among pregnant
women, principally in Franceville (Haut-Ogooué region),
symptoms compatible with acute viral hepatitis were not
found frequently. In order to confirm the previous obser-
vation, a second epidemiological study, was conducted
among 391 pregnant women aged 25.9 ± 6.9 years (range,
14–45 years) in both rural and urban areas of the Haut-
Ogooué region. Of all these newly collected samples, 39
(10.0%) were positive for anti-HEV IgG (Table 2). A sig-
Table 1: Prevalence of anti-HEV IgG among pregnant women in the main cities of Gabon, central Africa, and in different age groups
Variable Prevalence of anti-HEV IgG
No. positive/No. tested % 95% CI OR 95% CI
Main Cities
Libreville 27/183 14.7 9.6–19.9 1.24 0.78–1.97
Port-Gentil 16/157 10.2 5.5–14.9 0.75 0.43–1.31
Lambaréné 39/304 12.8 9.1–16.5 0.99 0.66–1.49
Oyem 8/57 14.0 5.0–23.0 1.15 0.53–2.49
Franceville 29/139 20.8 14.1–27.5 2.05 1.29–3.26
Age range (years)
14–20 40/269 14.8 10.6–19.0 1.26 0.84–1.90
21–25 31/230 13.5 9.1–17.9 1.08 0.70–1.68
26–30 20/174 11.5 6.8–16.2 0.87 0.52–1.45
31–44 28/167 16.8 11.2–22.4 1.49 0.94–2.36
All 119/840 14.1 11.8–16.4
CI, confidence interval; OR, odds ratioVirology Journal 2008, 5:158 http://www.virologyj.com/content/5/1/158
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nificant difference (p  < 0.05) in prevalence was found
between urban (Franceville city; 13.5%) and rural areas
(villages of the Haut-Ogooué region; 6.4%), with a 2.5
times higher risk for infection in urban than in rural areas
(Table 2).
We have shown that HEV is highly prevalent in Gabon,
central Africa, although a study conducted in 1995 [17]
concluded that the virus was not present in this country.
The prevalence of anti-HEV IgG in this study was similar
to those in endemic and epidemic countries in South-East
Asia [18] and to that in south-west France, where autoch-
thonous HEV infection is frequently recorded [19].
In the first epidemiological study, in Franceville, 29 of 139
pregnant women had antibodies to HEV (20.8%). In the
second study, 28 of 207 women in the same city had HEV
antibodies (13.5%). The difference in prevalence between
the two studies was not statistically significant. The find-
ing that the prevalence in the first study was higher than
that in the second might be due to the fact that in the first
study the samples were collected from two maternal cent-
ers in which medical care is free and therefore women of
low socio-economic status frequently attend. In the sec-
ond study, in order to determine the true HEV prevalence
in the area, samples were collected from six sentinel cent-
ers, including clinics, hospitals, and maternity centers.
The difference may therefore be due to a difference in the
population studied and the higher HEV prevalence in
people of low socio-economic status.
Our finding of a higher risk for HEV infection in urban
than in rural areas suggests the presence of local risk fac-
tors; however, the source of contamination remains
unknown. The population density, the absence of sewer
systems, the consumption of bush meat and the presence
of excreta of peri-domestic animals near habitations
might also be risk factors [20-22]. Furthermore, the
excreta of HEV-infected persons might be contaminated,
again implicating the precarious sanitary conditions in cit-
ies in the country.
Until now, no epidemic or sporadic cases of HEV infec-
tion have been reported, despite the high prevalence of
antibodies to this virus. Furthermore, no liver markers
compatible with acute viral hepatitis were found that
would indicate past HEV infection among these pregnant
Gabonese women. Probably, the initial HEV infection
occurred early in life, and, as with early childhood expo-
sure to hepatitis A virus in countries where it is highly
endemic, the children do not become ill. Therefore, epide-
miological studies of people in various age groups and in
children are also needed.
Screening pregnant women for HEV is thus important for
improving knowledge about the epidemiology (transmis-
sion and circulation) of this virus. More extensive studies
should be conducted to evaluate the seroprevalence, to
characterize the circulating HEV genotypes and to deter-
mine the current pathological and risk status in the gen-
eral population of central Africa.
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